Tag: Amarin Corporation

March 19, 2019 Off

Amarin Corporation’s Vascepa significantly reduces total cardiovascular events in REDUCE-IT study

Amarin Corporation’s Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT, as presented in a cardiovascular outcomes study.

March 1, 2018 Off

Amarin Corporation’s cardiovascular study is nearing completion

By Dino Mustafić

Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.